Key Stats
52-Week Range
Choose a result to open the company. Use arrow keys to choose a result and Enter to confirm.
Choose a result to open the company. Use arrow keys to choose a result and Enter to confirm.
#1434 ๐บ๐ธ US
NASDAQยทTXG
$51.8000
โฌ47.21
-9.72% (24h)
Market Cap
$6.81B
โฌ6.21B
Volume (24h)
3.23M shrsยท $167.14M
โฌ152.31M
Last Close (7D)
$51.80
โฌ47.21
Prices in USD. No currency conversion.
52-Week Range
Q3 FY2026ended 2026-09-30 ยท filed 2026-11-06
$150.67M
$-19.43M
$-16.06M
-$0.15
N/A
$1.06B
$838.04M
N/A
For Q1 FY2026 ended March 31, 2026, 10x Genomics reported revenue of $150.8 million, a decrease of 2.6% year-over-year. Net loss narrowed to $13.5 million from $34.3 million, a 60.8% improvement. Operating loss improved 56.7% to $17.0 million, and diluted EPS was -$0.10, up 64.3% from -$0.28. Total equity stood at $814.3 million.
Estimates and expected reporting dates may change.
10x Genomics develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments
QuantumScale single cell RNA and single cell methylation kits, as well as Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample.
This platform includes HD WT panel gene expression, and HD 3' gene expression assays The Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides
Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing slides and reagents. It also provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature.
Its portfolio also includes Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization, and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns.
The company serves various academic, government, biopharmaceutical, biotechnology, and institutions. Incorporated in 2012 and headquartered in Pleasanton, California, 10x Genomics was formerly known as 10X Technologies, Inc. before rebranding in November 2014.
Quarterly report
Filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with unaudited financial statements and management's discussion of results.
10-Q
2026-11-06
SEC
Earnings results
Furnished a press release with its latest financial results (Item 2.02).
8-K ยท 2.02,9.01
2026-11-05
SEC
Officer / director change
Board appointed a new director on October 28, 2026 on recommendation of the Nominating and Corporate Governance Committee (Item 5.02).
8-K ยท 5.02
2026-11-02
SEC
Quarterly report
10x Genomics filed its quarterly report on Form 10-Q for Q2 FY2026 ended June 30, 2026, on August 7, 2026.
10-Q
2026-08-07
SEC
Earnings results
On August 6, 2026, 10x Genomics filed a Form 8-K reporting earnings results under Items 2.02 and 9.01.
8-K ยท 2.02,9.01
2026-08-06
SEC
Shareholder vote
On June 4, 2026, 10x Genomics held a shareholder vote, as reported in an 8-K filing.
8-K ยท 5.07
2026-06-08
SEC
Quarterly report
10x Genomics filed its quarterly report for Q1 FY2026 ended March 31, 2026.
10-Q
2026-05-08
SEC
Earnings results
On May 7, 2026, 10x Genomics reported its earnings results for Q1 FY2026.
8-K ยท 2.02,9.01
2026-05-07
SEC
Proxy statement
10x Genomics filed its proxy statement on April 24, 2026.
DEF 14A
2026-04-24
SEC
Annual report
10x Genomics filed its annual report for fiscal year 2025 on February 13, 2026.
10-K
2026-02-13
SEC
10x Genomics develops and sells instruments, consumables, and software for analyzing biological systems. Its main platforms include the Chromium platform for single-cell analysis, which enables the study of individual cells using microfluidic chips and related consumables, and the Visium platform for spatial analysis, which uses high-density DNA arrays to map the physical location of biological analytes within a tissue sample. The company also offers the Xenium Analyzer for in situ analysis, allowing researchers to detect RNA targets directly in tissue sections. Additionally, 10x Genomics provides software products such as Cell Ranger for single-cell RNA sequencing data processing, Loupe Browser for data visualization, and Xenium Explorer for in situ data exploration.
10x Genomics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol TXG. Its shares are traded in United States dollars (USD). The company is headquartered in the United States and operates primarily in the US market, with additional sales across the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific region.
10x Genomics operates in the Healthcare sector and is classified under the Health Information Services industry. This means the company provides technology and services that support healthcare and biological research, specifically focusing on analyzing biological systems at the single-cell and spatial levels. Its products are used by researchers in genomics, drug development, and diagnostics to gain insights into cellular biology and disease mechanisms.
10x Genomics offers several key platforms and products. The Chromium platform includes instruments like the Chromium X Series and microfluidic chips for single-cell analysis, along with kits such as QuantumScale for single-cell RNA and methylation analysis. The Visium platform provides spatial analysis tools, including HD WT panel gene expression assays and the Visium CytAssist instrument that transfers analytes from glass slides to Visium slides. The Xenium Analyzer enables in situ detection of RNA targets in tissue sections. The company also supplies related consumables, slides, and reagents. Software products include Cell Ranger for data processing, Loupe Browser for visualization, and Xenium Explorer for subcellular data exploration.
10x Genomics serves a global customer base. Its primary market is the United States, but it also sells to customers in the rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific region. The company's products are used by research institutions, pharmaceutical companies, and biotechnology firms worldwide to advance understanding of biological systems through single-cell and spatial analysis technologies.
Yahoo ยท Nov 21, 2026
10x Genomics Stock Gets A Diagnostics Push From New Research Deals
Yahoo ยท Nov 18, 2026
ARKK Is Down, But These 10 Cathie Wood Stocks Have Soared Up to 285% in 2026
SeekingAlpha ยท Nov 18, 2026
ARKK: Nvidia Is Not Cathie Wood's Biggest Bet
Yahoo ยท Nov 16, 2026
10x Genomics Expands Global Research in Blood-Based Diagnostics for Autoimmune Disease with Two New Collaborations
Benzinga ยท Nov 16, 2026
10x Genomics Collaborates With Charitรฉ And Seoul National University On Identifying Blood-Based Biomarkers Of Disease Activity And Treatment Response For Autoimmune Disease
Yahoo ยท Nov 12, 2026
10x Genomics' Xenium Platform to Support Breast Cancer Biomarker Study
Americas
Europe
Asia